Serena Williams’ triumphant return to competitive tennis has reignited a surprisingly thorny debate that stretches far beyond the court: Are GLP-1 weight-loss drugs giving athletes an unfair edge?
The 23-time Grand Slam champion returned to the court earlier this month at the Queen’s Club Championship for her first doubles competition in nearly four years, teaming up with 19-year-old Canadian doubles partner Victoria Mboko for a convincing win.
The 44-year-old’s performance immediately drew attention online, with some critics questioning whether her public use of the weight-loss drug tirzepatide could provide an athletic advantage.
The post Serena Williams Ignites Debate Over Athletes Taking GLP-1s appeared first on The Daily Beast
